Lorelei A Mucci, Scd

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3617295/publications.pdf

Version: 2024-02-01

384 papers	21,957 citations	10389 72 h-index	13379 130 g-index
392 all docs	392 docs citations	392 times ranked	32930 citing authors

#	Article	IF	Citations
1	p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up. European Urology Oncology, 2023, 6, 110-112.	5.4	3
2	A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. European Urology, 2023, 83, 343-351.	1.9	23
3	Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. International Journal of Epidemiology, 2023, 52, 71-86.	1.9	16
4	Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 771-774.	6.3	39
5	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. European Urology Oncology, 2022, 5, 18-29.	5.4	31
6	Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer and Prostatic Diseases, 2022, 25, 397-402.	3.9	37
7	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	7.0	28
8	Aspirin use and prostate tumor angiogenesis. Cancer Causes and Control, 2022, 33, 149-151.	1.8	4
9	Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. Molecular Oncology, 2022, 16, 2451-2469.	4.6	8
10	Association of plant-based diet index with prostate cancer risk. American Journal of Clinical Nutrition, 2022, 115, 662-670.	4.7	45
11	Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 320-326.	3.9	4
12	Longitudinal trajectories of lifetime body shape and prostate cancer angiogenesis. European Journal of Epidemiology, 2022, 37, 261-270.	5.7	4
13	First look at patient reported outcomes from IRONMAN, the international registry of men with advanced prostate cancer.. Journal of Clinical Oncology, 2022, 40, 69-69.	1.6	2
14	IRONMAN: The international registry for men with advanced prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS190-TPS190.	1.6	1
15	Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals. JNCI Cancer Spectrum, 2022, 6, .	2.9	7
16	5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	2.5	3
17	Validity and Relative Validity of Alternative Methods of Assessing Physical Activity in Epidemiologic Studies: Findings From the Menâ€™s Lifestyle Validation Study. American Journal of Epidemiology, 2022, 191, 1307-1322.	3.4	7
18	Plasma metabolite profiles related to plant-based diets and the risk of type 2 diabetes. Diabetologia, 2022, 65, 1119-1132.	6.3	35

#	Article	IF	Citations
19	Impact of neighborhood socioeconomic status, income segregation, and greenness on blood biomarkers of inflammation. Environment International, 2022, 162, 107164.	10.0	29
20	Circulating Insulin-Like Growth Factor 1â€“Related Biomarkers and Risk of Lethal Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, pkab091.	2.9	6
21	Urinary 6-sulfatoxymelatonin Levels and Prostate Cancer Risk among Men in the Multiethnic Cohort. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 688-691.	2.5	1
22	DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. JNCI Cancer Spectrum, 2022, 6, pkab097.	2.9	5
23	Racial Disparities in Prostate Cancer: Evaluation of Diet, Lifestyle, Family History, and Screening Patterns. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 982-990.	2.5	6
24	Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia. International Journal of Cancer, 2022, 151, 1033-1046.	5.1	18
25	The Impact of PIK3R1 Mutations and Insulinâ€“PI3Kâ€“Glycolytic Pathway Regulation in Prostate Cancer. Clinical Cancer Research, 2022, 28, 3603-3617.	7.0	7
26	Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. Journal of the National Cancer Institute, 2021, 113, 727-734.	6.3	36
27	Genetic ablation of <scp>FASN</scp> attenuates the invasive potential of prostate cancer driven by <scp>Pten</scp> loss. Journal of Pathology, 2021, 253, 292-303.	4.5	13
28	Posttraumatic stress disorder and suicide among veterans with prostate cancer. Psycho-Oncology, 2021, 30, 581-590.	2.3	5
29	Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. Journal of the National Cancer Institute, 2021, 113, 616-625.	6.3	40
30	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
31	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	3.9	16
32	Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2021, 39, 250-250.	1.6	0
33	Racial differences in aneuploidy in high-grade muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 400-400.	1.6	0
34	Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1000-1008.	2.5	2
35	Dairy consumption, plasma metabolites, and risk of type 2 diabetes. American Journal of Clinical Nutrition, 2021, 114, 163-174.	4.7	29
36	Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer. European Urology, 2021, 79, 405-412.	1.9	22

#	Article	IF	Citations
37	Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. JCO Global Oncology, 2021, 7, 495-505.	1.8	12
38	Exploratory assessment of pineal gland volume, composition, and urinary 6â€sulfatoxymelatonin levels on prostate cancer risk. Prostate, 2021, 81, 487-496.	2.3	3
39	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate, 2021, 81, 683-693.	2.3	5
40	Can there be consensus on whether vasectomy is a prostate cancer risk factor?. Prostate Cancer and Prostatic Diseases, 2021, 24, 939-941.	3.9	1
41	Prenatal and Perinatal Factors and Risk of Cancer in Middle and Older Adulthood among Men. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1841-1845.	2.5	2
42	Abstract 979: Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer. , 2021, , .		0
43	Abstract 2498: Identification and characterization of thePIK3R1-mutant subtype in PI3K-addicted prostate cancer. , 2021, , .		0
44	Abstract 863: Circadian gene expression in metastatic sites and association with survival in metastatic castration-resistant prostate cancer. , 2021, , .		0
45	Association of nut consumption with risk of total cancer and 5 specific cancers: evidence from 3 large prospective cohort studies. American Journal of Clinical Nutrition, 2021, 114, 1925-1935.	4.7	8
46	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). Cancers, 2021, 13, 4690.	3.7	11
47	Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 751-756.	2.5	1
48	Attenuation of SRC Kinase Activity Augments PARP Inhibitorâ€“mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. Clinical Cancer Research, 2021, 27, 1792-1806.	7.0	13
49	Is Vasectomy a Cause of Prostate Cancer?. Journal of the National Cancer Institute, 2020, 112, 5-6.	6.3	2
50	Family history of prostate cancer and the incidence of ERGâ€•and phosphatase and tensin homologâ€defined prostate cancer. International Journal of Cancer, 2020, 146, 2694-2702.	5.1	3
51	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 83-93.	1.6	24
52	Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clinical Cancer Research, 2020, 26, 2047-2064.	7.0	77
53	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1086-1093.	7.0	35
54	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 410-418.	3.9	17

#	Article	IF	Citations
55	Concerning trends in colorectal cancer in the wake of Chadwick Bosemanâ€™s death. Journal of Cancer Policy, 2020, 26, 100260.	1.4	0
56	Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health, The, 2020, 5, e475-e483.	10.0	1,595
57	Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma. Environmental Research, 2020, 190, 109781.	7.5	6
58	Metabolomic Signatures of Long-term Coffee Consumption and Risk of Type 2 Diabetes in Women. Diabetes Care, 2020, 43, 2588-2596.	8.6	27
59	Racial Differences in Genomic Profiling of Prostate Cancer. New England Journal of Medicine, 2020, 383, 1083-1085.	27.0	87
60	Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cellâ€“Level PI3K Pathway Activation. Clinical Cancer Research, 2020, 26, 5903-5913.	7.0	8
61	Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial. Prostate, 2020, 80, 1304-1313.	2.3	8
62	The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1283-1289.	2.5	34
63	The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. European Heart Journal, 2020, 41, 2645-2656.	2.2	138
64	The association of diabetes with risk of prostate cancer defined by clinical and molecular features. British Journal of Cancer, 2020, 123, 657-665.	6.4	31
65	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis, 2020, 41, 904-908.	2.8	1
66	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1374-1380.	2.5	57
67	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	1.6	170
68	A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study. Metabolites, 2020, 10, 99.	2.9	12
69	Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. European Urology, 2020, 78, 637-639.	1.9	5
70	Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers. Neoplasia, 2020, 22, 154-161.	5.3	15
71	Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discovery, 2020, 10, 783-791.	9.4	1,286
72	Baldness and Risk of Prostate Cancer in the Health Professionals Follow-up Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1229-1236.	2.5	5

#	Article	IF	Citations
73	TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?. Cancer Discovery, 2020, 10, 779-782.	9.4	329
74	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Network Open, 2020, 3, e2030072.	5.9	87
75	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. PLoS ONE, 2020, 15, e0243928.	2.5	13
76	Long-term cancer survival in cohorts of U.S. health professionals.. Journal of Clinical Oncology, 2020, 38, 12075-12075.	1.6	0
77	5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care.. Journal of Clinical Oncology, 2020, 38, 39-39.	1.6	0
78	Tumor protein expression of BRCA1 and development of lethal prostate cancer.. Journal of Clinical Oncology, 2020, 38, 65-65.	1.6	0
79	Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness.. Journal of Clinical Oncology, 2020, 38, 347-347.	1.6	4
80	COVID-19 and cancer in the United States. Epidemiologia E Prevenzione, 2020, 44, 26-27.	1.1	1
81	Association of genetic variation of the six gene prognostic model for castrationâ€resistant prostate cancer with survival. Prostate, 2019, 79, 73-80.	2.3	6
82	Relation between tobacco control policies and population at high risk of lung cancer in the European Union. Environmental Research, 2019, 179, 108594.	7.5	10
83	Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women. Journal of Nutrition, 2019, 149, 1215-1221.	2.9	11
84	The Nordic Twin Study on Cancer â€" NorTwinCan. Twin Research and Human Genetics, 2019, 22, 817-823.	0.6	11
85	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nature Communications, 2019, 10, 4358.	12.8	109
86	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
87	Circulating inflammation markers and prostate cancer. Prostate, 2019, 79, 1338-1346.	2.3	15
88	Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGESâ€Reykjavik study. Cancer, 2019, 125, 2877-2885.	4.1	37
89	Prostate Cancer National Summitâ€™s Call to Action. Clinical Genitourinary Cancer, 2019, 17, 161-168.	1.9	0
90	Aneuploidy drives lethal progression in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11390-11395.	7.1	101

#	Article	IF	Citations
91	Cancer Incidence and Mortality in 260,000 Nordic Twins With 30,000 Prospective Cancers. Twin Research and Human Genetics, 2019, 22, 99-107.	0.6	21
92	Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. Journal of Clinical Oncology, 2019, 37, 1499-1511.	1.6	29
93	Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1052-1058.	2.5	14
94	Coffee consumption and plasma biomarkers of metabolic and inflammatory pathways in US health professionals. American Journal of Clinical Nutrition, 2019, 109, 635-647.	4.7	59
95	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGFâ€I, IGFâ€II, IGFBPâ€1, IGFBPâ€2 and IGFBPâ€3 in a pooled analysis of 16,024 men from 22 studies. International Journal of Cancer, 2019, 145, 3244-3256.	5.1	14
96	The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies. American Journal of Epidemiology, 2019, 188, 991-1012.	3.4	81
97	Pre-diagnostic 25-hydroxyvitamin D levels and survival in cancer patients. Cancer Causes and Control, 2019, 30, 333-342.	1.8	8
98	A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 2047-2054.	2.5	11
99	Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. European Urology Oncology, 2019, 2, 126-134.	5.4	11
100	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	1.9	43
101	Circulating 25â€hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer. International Journal of Cancer, 2019, 144, 2401-2407.	5.1	14
102	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 584-590.	2.5	8
103	Metabolic Factors and Prostate Cancer Risk. Clinical Chemistry, 2019, 65, 42-44.	3.2	9
104	Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 707-714.	2.5	11
105	Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality. Prostate Cancer and Prostatic Diseases, 2019, 22, 284-291.	3.9	4
106	Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Molecular Cancer Research, 2019, 17, 446-456.	3.4	44
107	Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 32-37.	1.9	4
108	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	2.5	21

#	Article	IF	Citations
109	Guideline-Based Physical Activity and Survival Among US Men With Nonmetastatic Prostate Cancer. American Journal of Epidemiology, 2019, 188, 579-586.	3.4	16
110	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. European Urology, 2019, 76, 33-40.	1.9	26
111	Association between Trichomonas vaginalis and prostate cancer mortality. International Journal of Cancer, 2019, 144, 2377-2380.	5.1	21
112	Diet and Lifestyle in Prostate Cancer. Advances in Experimental Medicine and Biology, 2019, 1210, 1-27.	1.6	26
113	The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.. Journal of Clinical Oncology, 2019, 37, 243-243.	1.6	2
114	Methylation-associated miR193b silencing activates master drivers of aggressive prostate cancer.. Journal of Clinical Oncology, 2019, 37, 240-240.	1.6	0
115	A randomized trial of exercise on quality of life in men with metastatic prostate cancer: The ExPeCT Trial.. Journal of Clinical Oncology, 2019, 37, 97-97.	1.6	9
116	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 783-789.	2.5	1
117	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 298-299.	4.4	0
118	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2018, 199, 1417-1425.	0.4	70
119	The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030361.	6.2	461
120	Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate, 2018, 78, 233-238.	2.3	5
121	Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 193-200.	2.5	18
122	MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 201-207.	2.5	21
123	Midlife metabolic factors and prostate cancer risk in later life. International Journal of Cancer, 2018, 142, 1166-1173.	5.1	18
124	Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. IScience, 2018, 9, 451-460.	4.1	69
125	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	12.8	43
126	Smoking cessation among men following cancer diagnosis: a matched cohort study. Journal of Cancer Survivorship, 2018, 12, 786-793.	2.9	8

#	Article	IF	Citations
127	Dietary Acrylamide Intake and Risk of Renal Cell Carcinoma in Two Large Prospective Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 979-982.	2.5	13
128	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open, 2018, 8, e022899.	1.9	85
129	Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency. European Urology, 2018, 74, 545-548.	1.9	5
130	Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clinical Cancer Research, 2018, 24, 5910-5917.	7.0	52
131	Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors. Prostate, 2018, 78, 1172-1180.	2.3	17
132	Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort. Cancer Prevention Research, 2018, 11, 621-628.	1.5	15
133	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 2018, 39, 1431-1437.	2.8	35
134	A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1231-1233.	2.5	2
135	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
136	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
137	Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer Causes and Control, 2018, 29, 775-784.	1.8	3
138	Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discovery, 2018, 8, 803-811.	9.4	62
139	ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. Journal of Clinical Investigation, 2018, 128, 2979-2995.	8.2	53
140	Dietary acrylamide intake and risk of renal cell carcinoma in two large prospective cohorts.. Journal of Clinical Oncology, 2018, 36, 677-677.	1.6	0
141	Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer.. Journal of Clinical Oncology, 2018, 36, 240-240.	1.6	0
142	Regulation of the tumor suppressor PLZF and prostate cancer prognosis.. Journal of Clinical Oncology, 2018, 36, 137-137.	1.6	0
143	Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression.. Journal of Clinical Oncology, 2018, 36, 5044-5044.	1.6	0
144	Circulating Antioxidant Levels and Risk of Prostate Cancer byTMPRSS2:ERG. Prostate, 2017, 77, 647-653.	2.3	11

#	Article	IF	Citations
145	Perineural Invasion and Risk of Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 719-726.	2.5	51
146	The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. Cancer, 2017, 123, 1490-1496.	4.1	6
147	CanWalk: a feasibility study with embedded randomised controlled trial pilot of a walking intervention for people with recurrent or metastatic cancer. BMJ Open, 2017, 7, e013719.	1.9	31
148	Familial Risk and Heritability of Colorectal Cancer in the Nordic Twin Study of Cancer. Clinical Gastroenterology and Hepatology, 2017, 15, 1256-1264.	4.4	77
149	Dairy intake in relation to prostate cancer survival. International Journal of Cancer, 2017, 140, 2060-2069.	5.1	32
150	Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physiciansâ€™ Health Study. European Urology, 2017, 72, 821-827.	1.9	44
151	Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8â€“10 Prostate Cancer. Eur Urol 2017;71:907â€“12. European Urology, 2017, 72, e9-e10.	1.9	1
152	Lung cancer, genetic predisposition and smoking: the Nordic Twin Study of Cancer. Thorax, 2017, 72, 1021-1027.	5.6	27
153	Prostate cancer incidence as an iceberg. European Journal of Epidemiology, 2017, 32, 477-479.	5.7	0
154	Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. International Journal of Cancer, 2017, 141, 933-944.	5.1	44
155	Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis, 2017, 38, 806-811.	2.8	93
156	Expression and Genetic Variation in Neuroendocrine Signaling Pathways in Lethal and Nonlethal Prostate Cancer among Men Diagnosed with Localized Disease. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1781-1787.	2.5	6
157	Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. International Journal of Cancer, 2017, 141, 1794-1802.	5.1	28
158	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology, 2017, 153, 1284-1294.e1.	1.3	189
159	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer, 2017, 123, 4130-4138.	4.1	11
160	The impact of statin use on the efficacy of abiraterone acetate in patients with castrationâ€resistant prostate cancer. Prostate, 2017, 77, 1303-1311.	2.3	19
161	A Walking Intervention Among Men With Prostate Cancer: A Pilot Study. Clinical Genitourinary Cancer, 2017, 15, e1021-e1028.	1.9	20
162	Early Life Residence, Fish Consumption, and Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 346-354.	2.5	20

#	Article	IF	Citations
163	Common medications and prostate cancer mortality: a review. World Journal of Urology, 2017, 35, 875-882.	2.2	15
164	Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clinical Cancer Research, 2017, 23, 81-87.	7.0	58
165	Reply to CÃ©dric Annweiler, Pierre Bigot, and Spyridon N. Karrasâ€™ Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974â€“82. European Urology, 2017, 71, e18.	1.9	0
166	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. Trials, 2017, 18, 456.	1.6	6
167	Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?. Journal of Clinical Oncology, 2017, 35, 3272-3274.	1.6	6
168	Long-term aspirin use and intratumoral gene expression in prostate cancer.. Journal of Clinical Oncology, 2017, 35, 106-106.	1.6	0
169	Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5062-5062.	1.6	1
170	Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate, 2016, 76, 691-699.	2.3	21
171	Body size across the life course and prostate cancer in the <scp>H</scp>ealth <scp>P</scp>rofessionals <scp>F</scp>ollowâ€up <scp>S</scp>tudy. International Journal of Cancer, 2016, 138, 853-865.	5.1	48
172	Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes and Control, 2016, 27, 1043-1047.	1.8	5
173	The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer & Metabolism, 2016, 4, 22.	5.0	26
174	Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study. BMC Cancer, 2016, 16, 438.	2.6	16
175	Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. European Urology, 2016, 70, 974-982.	1.9	72
176	Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 745-749.	2.5	23
177	Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 887-906.	2.5	98
178	Reply to Herney AndrÃ©s GarcÃa-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974â€“82. European Urology, 2016, 70, e156-e157.	1.9	0
179	Selenium- or Vitamin Eâ€“Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1050-1058.	2.5	55
180	Snus use, smoking and survival among prostate cancer patients. International Journal of Cancer, 2016, 139, 2753-2759.	5.1	27

#	Article	IF	Citations
181	Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. Cancer Prevention Research, 2016, 9, 933-941.	1.5	18
182	Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men. Journal of Biological Rhythms, 2016, 31, 461-469.	2.6	26
183	CHALLENGE Trial 1 Year Feasibility Resultsâ€"Letter. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1277-1277.	2.5	0
184	Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. Cancer Causes and Control, 2016, 27, 1361-1370.	1.8	79
185	Sniffing out significant â€œPee valuesâ€• genome wide association study of asparagus anosmia. BMJ, The, 2016, 355, i6071.	6.0	11
186	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2705-2711.	1.6	74
187	Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Research, 2016, 76, 4785-4790.	0.9	61
188	Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2520-2527.	3.6	30
189	Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. Cancer Causes and Control, 2016, 27, 1049-1058.	1.8	30
190	Risk of prostate cancerâ€specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU International, 2016, 118, 919-926.	2.5	10
191	Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis, 2016, 37, 262-268.	2.8	7
192	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. American Journal of Clinical Nutrition, 2016, 103, 851-860.	4.7	65
193	Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression. Cancer Research, 2016, 76, 1869-1881.	0.9	29
194	Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. British Journal of Cancer, 2016, 114, 939-944.	6.4	19
195	Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 302-308.	2.5	41
196	Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA - Journal of the American Medical Association, 2016, 315, 68.	7.4	648
197	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. European Urology, 2016, 70, 549-552.	1.9	121
198	The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 145-150.	2.5	80

#	Article	IF	Citations
199	Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clinical Cancer Research, 2016, 22, 765-772.	7.0	25
200	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clinical Cancer Research, 2016, 22, 448-458.	7.0	29
201	Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL) Tj ETQq1 1 0.784314 rgBT /Ov Oncology, 2016, 34, TPS5092-TPS5092.	1.6	9
202	The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, 196-196.	1.6	1
203	Increased cholesterol synthesis via squalene monooxygenase to predict lethal prostate cancer.. Journal of Clinical Oncology, 2016, 34, 77-77.	1.6	1
204	Computational Reconstruction of NFÎºB Pathway Interaction Mechanisms during Prostate Cancer. PLoS Computational Biology, 2016, 12, e1004820.	3.2	27
205	Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study.. Journal of Clinical Oncology, 2016, 34, 306-306.	1.6	0
206	Precision prevention of TMPRSS2:ERG prostate cancer.. Journal of Clinical Oncology, 2016, 34, 78-78.	1.6	0
207	Differential gene expression in prostate tissue according to vasectomy.. Journal of Clinical Oncology, 2016, 34, 298-298.	1.6	0
208	Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by TMPRSS2:ERG status.. Journal of Clinical Oncology, 2016, 34, 93-93.	1.6	0
209	Gene expression in prostate tissue according to frequency of ejaculation.. Journal of Clinical Oncology, 2016, 34, 25-25.	1.6	0
210	Expression and genetic variants in stress-related signaling pathways in lethal and nonlethal prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5032-5032.	1.6	0
211	Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study. Prostate, 2015, 75, 1384-1393.	2.3	25
212	ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate, 2015, 75, 1677-1681.	2.3	14
213	The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate, 2015, 75, 897-906.	2.3	26
214	Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate, 2015, 75, 1926-1933.	2.3	8
215	Insufficient Sleep and Risk of Prostate Cancer in a Large Swedish Cohort. Sleep, 2015, 38, 1405-1410.	1.1	35
216	Survivorship and Improving Quality of Life in Men with Prostate Cancer. European Urology, 2015, 68, 374-383.	1.9	91

#	Article	IF	Citations
217	Dimitrios Trichopoulos: In Memoriam (1938â€“2014). Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 483-483.	2.5	0
218	A Large Multiethnic Genome-Wide Association Study of Prostate Cancer Identifies Novel Risk Variants and Substantial Ethnic Differences. Cancer Discovery, 2015, 5, 878-891.	9.4	111
219	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. Journal of the National Cancer Institute, 2015, 108, djv346.	6.3	149
220	Risk of Sex-Specific Cancers in Opposite-Sex and Same-Sex Twins in Denmark and Sweden. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1622-1628.	2.5	16
221	No Association of ApoE Genotype with Risk of Prostate Cancer: A Nested Caseâ€“Control Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1632-1634.	2.5	9
222	Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prevention Research, 2015, 8, 737-742.	1.5	11
223	Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men. European Urology, 2015, 67, 191-194.	1.9	74
224	Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. International Journal of Cancer, 2015, 137, 949-958.	5.1	17
225	Reply to D.C. Sokal et al. Journal of Clinical Oncology, 2015, 33, 670-671.	1.6	0
226	Circulating vitamin D, vitamin Dâ€“related genetic variation, and risk of fatal prostate cancer in the <scp>N</scp>ational <scp>C</scp>ancer <scp>I</scp>nstitute <scp>B</scp>reast and <scp>P</scp>rostate <scp>C</scp>ancer <scp>C</scp>ohort <scp>C</scp>onsortium. Cancer, 2015, 121, 1949-1956.	4.1	50
227	Circadian clock genes and risk of fatal prostate cancer. Cancer Causes and Control, 2015, 26, 25-33.	1.8	39
228	GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clinical Genitourinary Cancer, 2015, 13, 370-377.e1.	1.9	8
229	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncology, 2015, 1, 495.	7.1	118
230	Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis, 2015, 36, 632-638.	2.8	34
231	CanWalk: study protocol for a randomized feasibility trial of a walking intervention for people with recurrent or metastatic cancer. Pilot and Feasibility Studies, 2015, 1, 7.	1.2	1
232	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 374-381.	2.8	22
233	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. European Urology, 2015, 68, 1076-1082.	1.9	12
234	Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis, 2015, 36, 639-647.	2.8	25

#	Article	IF	Citations
235	Physical Activity from Early Adulthood and Risk of Prostate Cancer: A 24-Year Follow-Up Study among Icelandic Men. Cancer Prevention Research, 2015, 8, 905-911.	1.5	17
236	Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study. Cancer Prevention Research, 2015, 8, 962-967.	1.5	20
237	Persistence of Trichomonas vaginalis serostatus in men over time. Cancer Causes and Control, 2015, 26, 1461-1466.	1.8	3
238	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Molecular Cancer Research, 2015, 13, 1431-1440.	3.4	15
239	Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. Cancer Causes and Control, 2015, 26, 1751-1759.	1.8	7
240	Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study. American Journal of Clinical Nutrition, 2015, 101, 173-183.	4.7	76
241	Association of Prostate Cancer Risk Variants with Gene Expression in Normal and Tumor Tissue. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 255-260.	2.5	97
242	Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: Results from the Health Professionals Follow-up Study. European Urology, 2015, 67, 432-438.	1.9	79
243	Cholesterol metabolism and prostate cancer-specific mortality.. Journal of Clinical Oncology, 2015, 33, 12-12.	1.6	1
244	Familial risk and heritability of genitourinary cancers in the Nordic Twin Cohorts.. Journal of Clinical Oncology, 2015, 33, 11-11.	1.6	0
245	Discovery and validation of a 30-gene expression signature to identify prostate cancer patients who are candidates for active surveillance.. Journal of Clinical Oncology, 2015, 33, 10-10.	1.6	0
246	Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2015, 33, 148-148.	1.6	0
247	Is active surveillance safe for obese patients?. Nature Reviews Urology, 2014, 11, 489-490.	3.8	1
248	Elevated insulinâ€like growth factor binding proteinâ€1 (IGFBPâ€1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate, 2014, 74, 225-234.	2.3	33
249	5Î±-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1301.	5.1	38
250	Interrogation of <scp>ERG</scp> gene rearrangements in prostate cancer identifies a prognostic 10â€gene signature with relevant implication to patients' clinical outcome. BJU International, 2014, 113, 309-319.	2.5	22
251	Total antioxidant intake in relation to prostate cancer incidence in the Health Professionals Followâ€Up Study. International Journal of Cancer, 2014, 134, 1156-1165.	5.1	20
252	Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. European Urology, 2014, 65, 1069-1075.	1.9	75

#	Article	IF	Citations
253	Elevated ILâ€8, TNFâ€Î±, and MCPâ€1 in men with metastatic prostate cancer starting androgenâ€deprivation therapy (ADT) are associated with shorter time to castrationâ€resistance and overall survival. Prostate, 2014, 74, 820-828.	2.3	66
254	SPINK1 Protein Expression and Prostate Cancer Progression. Clinical Cancer Research, 2014, 20, 4904-4911.	7.0	71
255	RE: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. Journal of the National Cancer Institute, 2014, 106, dju018-dju018.	6.3	4
256	Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERGâ€"Positive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2027-2031.	2.5	28
257	Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 1-2.	1.6	126
258	The Heritability of Prostate Cancer in the Nordic Twin Study of Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2303-2310.	2.5	169
259	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
260	Genetic variation across C-reactive protein and risk of prostate cancer. Prostate, 2014, 74, 1034-1042.	2.3	14
261	Prediagnostic Circulating Sex Hormones Are Not Associated with Mortality for Men with Prostate Cancer. European Urology, 2014, 65, 683-689.	1.9	27
262	Dietary Lycopene, Angiogenesis, and Prostate Cancer: A Prospective Study in the Prostate-Specific Antigen Era. Journal of the National Cancer Institute, 2014, 106, djt430-djt430.	6.3	174
263	Metformin Use and Prostate Cancer Risk. European Urology, 2014, 66, 1012-1020.	1.9	109
264	ABO blood group and risk of lethal prostate cancer.. Journal of Clinical Oncology, 2014, 32, 69-69.	1.6	1
265	Circadian dysrhythm and advanced prostate cancer.. Journal of Clinical Oncology, 2014, 32, 199-199.	1.6	0
266	Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study. Cancer Causes and Control, 2013, 24, 1575-1581.	1.8	15
267	Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2354-2363.	2.5	99
268	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1984-1993.	2.5	41
269	Associations between Dietary Acrylamide Intake and Plasma Sex Hormone Levels. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2024-2036.	2.5	36
270	Lifetime body size and prostate cancer risk in a population-based caseâ€"control study in Sweden. Cancer Causes and Control, 2013, 24, 2143-2155.	1.8	22

#	Article	IF	Citations
271	Whole Milk Intake Is Associated with Prostate Cancer-Specific Mortality among U.S. Male Physicians. Journal of Nutrition, 2013, 143, 189-196.	2.9	82
272	Shiftwork and Prostate-Specific Antigen in the National Health and Nutrition Examination Survey. Journal of the National Cancer Institute, 2013, 105, 1292-1297.	6.3	63
273	Diagnostic tests in urology: magnetic resonance imaging (<scp>MRI</scp>) for the staging of prostate cancer. BJU International, 2013, 111, 514-517.	2.5	3
274	Sleep Disruption Among Older Men and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 872-879.	2.5	79
275	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. Journal of the National Cancer Institute, 2013, 105, 1881-1890.	6.3	80
276	ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes and Development, 2013, 27, 683-698.	5.9	163
277	Mediterranean Diet Score and prostate cancer risk in a Swedish population-based caseâ€“control study. Journal of Nutritional Science, 2013, 2, e15.	1.9	32
278	A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clinical Cancer Research, 2013, 19, 1612-1619.	7.0	20
279	Gleason Grade Progression Is Uncommon. Cancer Research, 2013, 73, 5163-5168.	0.9	76
280	Common Genetic Variation of the Calcium-Sensing Receptor and Lethal Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 118-126.	2.5	23
281	Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death. Cancer Discovery, 2013, 3, 1130-1141.	9.4	77
282	Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate, 2013, 73, 700-705.	2.3	25
283	Use of 5Â-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ, The, 2013, 346, f3406-f3406.	6.0	34
284	ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. Journal of Clinical Investigation, 2013, 123, 1109-1122.	8.2	227
285	Consumption of Fish Products across the Lifespan and Prostate Cancer Risk. PLoS ONE, 2013, 8, e59799.	2.5	37
286	Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer.. Journal of Clinical Oncology, 2013, 31, 2-2.	1.6	0
287	Ejaculation frequency and prostate cancer: A large, prospective study with 16 years of follow-up.. Journal of Clinical Oncology, 2013, 31, 5078-5078.	1.6	0
288	Vasectomy and risk of lethal prostate cancer: A 24-year prospective study.. Journal of Clinical Oncology, 2013, 31, 5086-5086.	1.6	0

#	Article	IF	Citations
289	Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis, 2012, 33, 404-412.	2.8	48
290	Dietary Fatty Acid Intake and Prostate Cancer Survival in Orebro County, Sweden. American Journal of Epidemiology, 2012, 176, 240-252.	3.4	67
291	Increasing Use of Radical Prostatectomy for Nonlethal Prostate Cancer in Sweden. Clinical Cancer Research, 2012, 18, 6742-6747.	7.0	27
292	Milk Intake in Early Life and Risk of Advanced Prostate Cancer. American Journal of Epidemiology, 2012, 175, 144-153.	3.4	63
293	Milk and Dairy Consumption among Men with Prostate Cancer and Risk of Metastases and Prostate Cancer Death. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 428-436.	2.5	68
294	The Nordic Nutrition Recommendations and prostate cancer risk in the Cancer of the Prostate in Sweden (CAPS) study. Public Health Nutrition, 2012, 15, 1897-1908.	2.2	5
295	Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian Journal of Andrology, 2012, 14, 365-374.	1.6	100
296	Vitamin Dâ€"Related Genetic Variation, Plasma Vitamin D, and Risk of Lethal Prostate Cancer: A Prospective Nested Caseâ€"Control Study. Journal of the National Cancer Institute, 2012, 104, 690-699.	6.3	196
297	Circadian Disruption, Sleep Loss, and Prostate Cancer Risk: A Systematic Review of Epidemiologic Studies. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1002-1011.	2.5	131
298	The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1497-1509.	2.5	268
299	Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer. Journal of the National Cancer Institute, 2012, 104, 1335-1342.	6.3	126
300	Genetic variation in the tollâ€like receptor 4 and prostate cancer incidence and mortality. Prostate, 2012, 72, 209-216.	2.3	22
301	Î±â€Methylacylâ€CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Followâ€up Study. Prostate, 2012, 72, 301-306.	2.3	9
302	Dietary acrylamide and risk of prostate cancer. International Journal of Cancer, 2012, 131, 479-487.	5.1	39
303	Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes and Control, 2012, 23, 1359-1366.	1.8	6
304	Rye bread consumption in early life and reduced risk of advanced prostate cancer. Cancer Causes and Control, 2012, 23, 941-950.	1.8	24
305	Insomnia among elderly men and risk of prostate cancer.. Journal of Clinical Oncology, 2012, 30, 78-78.	1.6	6
306	Rye bread consumption in early life and reduced risk of advanced prostate cancer.. Journal of Clinical Oncology, 2012, 30, 79-79.	1.6	0

#	Article	IF	Citations
307	Association of metabolic syndrome with poorer prostate cancer and overall survival in men receiving androgen deprivation therapy (ADT) for biochemical relapse.. Journal of Clinical Oncology, 2012, 30, 4555-4555.	1.6	0
308	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature, 2011, 470, 269-273.	27.8	462
309	Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression. Journal of Clinical Oncology, 2011, 29, 2378-2385.	1.6	130
310	Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis, 2011, 32, 853-859.	2.8	36
311	Inflammation, Focal Atrophic Lesions, and Prostatic Intraepithelial Neoplasia with Respect to Risk of Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2280-2287.	2.5	68
312	Prognostic Determinants in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 429-437.	2.0	48
313	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2618-2627.	2.5	50
314	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2391-2396.	1.6	140
315	Dietary zinc and prostate cancer survival in a Swedish cohort. American Journal of Clinical Nutrition, 2011, 93, 586-593.	4.7	57
316	Coffee Consumption and Prostate Cancer Risk and Progression in the Health Professionals Follow-up Study. Journal of the National Cancer Institute, 2011, 103, 876-884.	6.3	127
317	Prediagnostic Plasma Vitamin D Metabolites and Mortality among Patients with Prostate Cancer. PLoS ONE, 2011, 6, e18625.	2.5	80
318	Hospitalization for osteoarthritis and prostate cancer specific mortality among Swedish men with prostate cancer. Cancer Epidemiology, 2010, 34, 644-647.	1.9	2
319	Homogeneous Prostate Cancer Mortality in the Nordic Countries Over Four Decades. European Urology, 2010, 58, 427-432.	1.9	7
320	Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer. Cancer Research, 2010, 70, 3136-3139.	0.9	110
321	An Exploration of Shared Genetic Risk Factors Between Periodontal Disease and Cancers: A Prospective Co-Twin Study. American Journal of Epidemiology, 2010, 171, 253-259.	3.4	86
322	Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival. Journal of Clinical Oncology, 2010, 28, 3958-3964.	1.6	113
323	Genome-wide Association Study of Prostate Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2869-2876.	2.5	46
324	A Large Prospective Study of SEP15 Genetic Variation, Interaction with Plasma Selenium Levels, and Prostate Cancer Risk and Survival. Cancer Prevention Research, 2010, 3, 604-610.	1.5	79

#	Article	IF	Citations
325	Plasma Levels of Acid-Labile Subunit, Free Insulin-Like Growth Factor-I, and Prostate Cancer Risk: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 484-491.	2.5	16
326	A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians â€. Human Molecular Genetics, 2010, 19, 3089-3101.	2.9	47
327	A 25-Year Prospective Study of Plasma Adiponectin and Leptin Concentrations and Prostate Cancer Risk and Survival. Clinical Chemistry, 2010, 56, 34-43.	3.2	137
328	Fish consumption and prostate cancer risk: a review and meta-analysis. American Journal of Clinical Nutrition, 2010, 92, 1223-1233.	4.7	167
329	A Prospective Study on Dietary Acrylamide Intake and the Risk for Breast, Endometrial, and Ovarian Cancers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2503-2515.	2.5	87
330	Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis. PLoS Genetics, 2010, 6, e1001204.	3.5	82
331	Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis, 2010, 31, 1597-1603.	2.8	54
332	Alcohol influence on acrylamide to glycidamide metabolism assessed with hemoglobin-adducts and questionnaire data. Food and Chemical Toxicology, 2010, 48, 820-824.	3.6	23
333	Immediate Risk of Suicide and Cardiovascular Death After a Prostate Cancer Diagnosis: Cohort Study in the United States. Journal of the National Cancer Institute, 2010, 102, 307-314.	6.3	156
334	The Plight of the Potato: Is Dietary Acrylamide a Risk Factor for Human Cancer?. Journal of the National Cancer Institute, 2009, 101, 618-621.	6.3	26
335	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. Journal of the National Cancer Institute, 2009, 101, 519-532.	6.3	328
336	Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 595-600.	2.5	60
337	One-carbon metabolism-related nutrients and prostate cancer survival. American Journal of Clinical Nutrition, 2009, 90, 561-569.	4.7	30
338	Immediate Risk for Cardiovascular Events and Suicide Following a Prostate Cancer Diagnosis: Prospective Cohort Study. PLoS Medicine, 2009, 6, e1000197.	8.4	103
339	Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality. Clinical Cancer Research, 2009, 15, 3223-3230.	7.0	46
340	Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study. Journal of Clinical Oncology, 2009, 27, 5627-5633.	1.6	117
341	Do Genetic Factors Explain the Association Between Poor Oral Health and Cardiovascular Disease? A Prospective Study Among Swedish Twins. American Journal of Epidemiology, 2009, 170, 615-621.	3.4	38
342	Dietary Acrylamide Intake and Risk of Premenopausal Breast Cancer. American Journal of Epidemiology, 2009, 169, 954-961.	3.4	58

#	Article	IF	Citations
343	Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. Journal of Clinical Oncology, 2009, 27, 3459-3464.	1.6	329
344	Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression. Cancer Research, 2009, 69, 5568-5574.	0.9	110
345	Acrylamide exposure measured by food frequency questionnaire and hemoglobin adduct levels and prostate cancer risk in the Cancer of the Prostate in Sweden Study. International Journal of Cancer, 2009, 124, 2384-2390.	5.1	50
346	Circulating prediagnostic interleukinâ€6 and Câ€reactive protein and prostate cancer incidence and mortality. International Journal of Cancer, 2009, 124, 2683-2689.	5.1	98
347	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. International Journal of Cancer, 2009, 125, 1143-1146.	5.1	9
348	Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes and Control, 2009, 20, 663-670.	1.8	23
349	Birth spacing and maternal risk of invasive epithelial ovarian cancer in a Swedish nationwide cohort. Cancer Causes and Control, 2008, 19, 1131-1137.	1.8	4
350	Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of Î²-catenin in prostate cancer. Laboratory Investigation, 2008, 88, 1340-1348.	3.7	116
351	Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncology, The, 2008, 9, 1039-1047.	10.7	385
352	Vitamin D and Prostate Cancer Risk--A Less Sunny Outlook?. Journal of the National Cancer Institute, 2008, 100, 759-761.	6.3	10
353	Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1682-1688.	2.5	19
354	Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2008, 100, 815-825.	6.3	286
355	Acrylamide Intake through Diet and Human Cancer Risk. Journal of Agricultural and Food Chemistry, 2008, 56, 6013-6019.	5.2	82
356	Telomere length predicts survival independent of genetic influences. Aging Cell, 2007, 6, 769-774.	6.7	271
357	A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer. PLoS Medicine, 2007, 4, e103.	8.4	243
358	Identifying Health Maintenance Organization Membership Through Self-report of Health Plan Name. Journal of Public Health Management and Practice, 2006, 12, 278-287.	1.4	5
359	Mediterranean dietary pattern and mortality among young women: a cohort study in Sweden. British Journal of Nutrition, 2006, 96, 384-392.	2.3	131
360	Validity of Self-reported Health Plan Information in a Population-based Health Survey. Journal of Public Health Management and Practice, 2006, 12, 570-577.	1.4	9

#	Article	IF	Citations
361	Validity and Reliability of Self-Reported Total Energy Expenditure Using a Novel Instrument. European Journal of Epidemiology, 2006, 21, 227-236.	5.7	57
362	Prospective study of dietary acrylamide and risk of colorectal cancer among women. International Journal of Cancer, 2006, 118, 169-173.	5.1	89
363	When death appears best for the child with severe malignancy: a nationwide parental follow-up. Palliative Medicine, 2006, 20, 567-577.	3.1	15
364	Risk Assessment Criteria Applied to a Screening Exam: Implications for Improving the Efficiency of a Sealant Program. Journal of Public Health Dentistry, 2005, 65, 203-208.	1.2	4
365	The Role of Epidemiology in Understanding the Relationship between Dietary Acrylamide and Cancer Risk in Humans. , 2005, 561, 39-47.		16
366	Testâ€“retest reliability of colorectal testing questions on the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS). Preventive Medicine, 2005, 41, 303-311.	3.4	26
367	Birth Order, Sibship Size, and Housing Density in Relation to Tooth Loss and Periodontal Disease: A Cohort Study among Swedish Twins. American Journal of Epidemiology, 2004, 159, 499-506.	3.4	15
368	A prospective study of pregravid oral contraceptive use in relation to fetal growth. BJOG: an International Journal of Obstetrics and Gynaecology, 2004, 111, 989-995.	2.3	19
369	Maternal smoking during pregnancy and risk of brain tumors in the offspring. A prospective study of 1.4 million Swedish births. Cancer Causes and Control, 2004, 15, 997-1005.	1.8	63
370	Dietary acrylamide and risk of renal cell cancer. International Journal of Cancer, 2004, 109, 774-776.	5.1	105
371	Maternal smoking and childhood leukemia and lymphoma risk among 1,440,542 Swedish children. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1528-33.	2.5	25
372	Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (United States). Cancer Causes and Control, 2003, 14, 311-318.	1.8	101
373	Birthweight differences between USA and China and their relevance to breast cancer aetiology. International Journal of Epidemiology, 2003, 32, 193-198.	1.9	30
374	Nausea and Vomiting in Pregnancy in Relation to Prolactin, Estrogens, and Progesterone. Obstetrics and Gynecology, 2003, 101, 639-644.	2.4	51
375	Is Epidemiology Implicating Extremely Low Frequency Electric and Magnetic Fields in Childhood Leukemia?. Environmental Health and Preventive Medicine, 2002, 7, 33-39.	3.4	0
376	Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. British Journal of Obstetrics and Gynaecology, 2001, 108, 291-294.	0.9	27
377	Support for Condom Availability and Needle Exchange Programs Among Massachusetts Adults, 1997. AIDS Education and Prevention, 2001, 13, 365-376.	1.1	5
378	Are there age-dependent effects of diet on prostate cancer risk?. International Journal of Public Health, 2001, 46, 329-334.	2.6	6

#	Article	IF	Citations
379	Risk factors for cholangiocarcinoma in a low risk Caucasian population. International Journal of Public Health, 2001, 46, 182-185.	2.6	11
380	Alcoholism and risk for endometrial cancer. International Journal of Cancer, 2001, 93, 299-301.	5.1	13
381	The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology, 2001, 34, 714-718.	7.3	105
382	Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG: an International Journal of Obstetrics and Gynaecology, 2001, 108, 291-294.	2.3	21
383	Health status and health care use of Massachusetts women reporting partner abuse. American Journal of Preventive Medicine, 2000, 19, 302-307.	3.0	241
384	Diet and Hepatocellular Carcinoma: A Case-Control Study in Greece. Nutrition and Cancer, 2000, 38, 6-12.	2.0	61